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Eﬃ  cacy of systematic pelvic lymphadenectomy in 
endometrial cancer (MRC ASTEC trial): a randomised study
The writing committee on behalf of the ASTEC study group*
Summary
Background Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the standard surgery for stage I endometrial 
cancer. Systematic pelvic lymphadenectomy has been used to establish whether there is extra-uterine disease and as a 
therapeutic procedure; however, randomised trials need to be done to assess therapeutic eﬃ  cacy. The ASTEC surgical 
trial investigated whether pelvic lymphadenectomy could improve survival of women with endometrial cancer.
Methods From 85 centres in four countries, 1408 women with histologically proven endometrial carcinoma thought 
preoperatively to be conﬁ ned to the corpus were randomly allocated by a minimisation method to standard surgery 
(hysterectomy and BSO, peritoneal washings, and palpation of para-aortic nodes; n=704) or standard surgery plus 
lymphadenectomy (n=704). The primary outcome measure was overall survival. To control for postsurgical treatment, 
women with early-stage disease at intermediate or high risk of recurrence were randomised (independent of 
lymph-node status) into the ASTEC radiotherapy trial. Analysis was by intention to treat. This study is registered, 
number ISRCTN 16571884.
Findings After a median follow-up of 37 months (IQR 24–58), 191 women (88 standard surgery group, 
103 lymphadenectomy group) had died, with a hazard ratio (HR) of 1·16 (95% CI 0·87–1·54; p=0·31) in favour of 
standard surgery and an absolute diﬀ erence in 5-year overall survival of 1% (95% CI –4 to 6). 251 women died or had 
recurrent disease (107 standard surgery group, 144 lymphadenectomy group), with an HR of 1·35 (1·06–1·73; p=0·017) 
in favour of standard surgery and an absolute diﬀ erence in 5-year recurrence-free survival of 6% (1–12). With adjustment 
for baseline characteristics and pathology details, the HR for overall survival was 1·04 (0·74–1·45; p=0·83) and for 
recurrence-free survival was 1·25 (0·93–1·66; p=0·14). 
Interpretation Our results show no evidence of beneﬁ t in terms of overall or recurrence-free survival for pelvic 
lymphadenectomy in women with early endometrial cancer. Pelvic lymphadenectomy cannot be recommended as 
routine procedure for therapeutic purposes outside of clinical trials.
Funding Medical Research Council and National Cancer Research Network.
Introduction
Endometrial cancer is now the most common 
gynaecological malignancy in western Europe and North 
America. About 6400 women are aﬀ ected every year in 
the UK,1 81 500 in the European Union,2 and 40 100 women 
in North America.3 More than 90% of cases occur in 
women older than 50 years of age, with a median age of 
63 years. The incidence in older women (aged 60–69 years) 
increased in the UK by 19% between 1993 and 2001.1 It is 
the seventh most common cause of death from cancer in 
women in western Europe, accounting for 1–2% of all 
deaths from cancer. Roughly 75% of women survive for 
5 years.4 This high survival rate is attributable to most 
women being diagnosed at an early stage after post-
menopausal bleeding.2
At diagnosis, about three-quarters of women have disease 
conﬁ ned to the uterine corpus. Standard deﬁ nitive surgery 
includes hysterectomy and bilateral salpingo-oophor-
ectomy (BSO). Most tumours are of endometrioid type; 
other histological types include serous, mucinous, clear 
cell, and mixed epithelial. Endometrial tumours are graded 
as well (grade 1), moderately (grade 2), or poorly (grade 3) 
diﬀ erentiated, apart from clear cell and serous, which are 
generally regarded as grade 3. Endometrial cancer spreads 
beyond the uterus by inﬁ ltrating directly through the 
myometrium, extending into the cervix, and metastasising 
most often to the pelvic nodes and less frequently directly 
to the para-aortic nodes. Pelvic lymph-node metastases 
occur in about 10% of women with clinical stage I 
(ie, conﬁ ned to the corpus) endometrial cancer.5,6 Within 
stage I disease, 3–5% of women with well diﬀ erentiated 
tumours and superﬁ cial myometrial invasion will have 
lymph-node involvement. This proportion rises to roughly 
20% of women with poorly diﬀ erentiated tumours and 
deep myometrial invasion.6
In Europe, traditional management of women with 
stage I disease has consisted of surgery, which is typically 
combined with adjuvant radiotherapy for women whose 
pathological features suggest an increased risk of nodal 
metastases. Tumour type, grade, and depth of myometrial 
invasion are key prognostic factors for recurrence, and 
are used to assess risk of recurrence and need for adjuvant 
treatment. A systematic review and meta-analysis of 
1770 patients from four randomised trials7 and data from 
the ASTEC/EN.5 radiotherapy trial8 show that adjuvant 
radiotherapy results in a small reduction in risk of isolated 
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pelvic recurrence (2·9%), but no evidence that it aﬀ ects 
overall or disease-speciﬁ c survival.
Since 1988, the International Federation of Gynaecology 
and Obstetrics (FIGO) classiﬁ cation of stage of endo metrial 
cancer has required a full systematic pelvic and para-aortic 
lymphadenectomy.9 Some propose that adjuvant radio-
therapy can be avoided and treatment morbidity reduced 
when lymphadenectomy shows no indication of disease in 
the nodes. However, evidence is scarce of a therapeutic 
beneﬁ t for lymphadenectomy in terms of survival. 
Lymphadenectomy is undertaken widely in North America 
and Australia, and data from non-randomised studies and 
case series, which have shown an association between 
lymphadenectomy and increased survival, lend support to 
the procedure.6,10,11 Other observational studies, however, 
have not shown any such beneﬁ t.12 ASTEC (A Study in the 
Treatment of Endometrial Cancer) was designed to assess 
the therapeutic beneﬁ t of lymph aden ectomy in endometrial 
cancer, independent of the eﬀ ect of adjuvant radiotherapy. 
ASTEC consisted of two trials with separate random-
isations that were designed to answer a surgical and a 
radiotherapy question (ﬁ gure 1). The surgical trial investi-
gated whether pelvic lymphadenectomy could improve 
survival of women with endometrial cancer, which was 
thought preoperatively to be conﬁ ned to the corpus. The 
radiotherapy trial addressed whether adjuvant external-
beam radiotherapy (EBRT) could improve survival of 
women with intermediate-risk and high-risk early-stage 
endometrial cancer. In this Article we report the results 
of the surgical randomisation.
Methods
Study design and women
We undertook a randomised controlled trial between 
July 1, 1998, and March 31, 2005 in 85 centres in four 
countries (UK, South Africa, Poland, and New Zealand). 
We included women with histologically proven 
endometrial carcinoma that was thought preoperatively 
to be conﬁ ned to the corpus, and those who were able to 
undergo both systematic lymphadenectomy and EBRT. 
Women who had a CT or MRI scan suggesting node 
enlargement were not excluded from randomisation. 
Specialist gynaecological surgeons who were experienced 
in pelvic lymphadenectomy undertook all surgical 
procedures. The same surgeon, who was speciﬁ ed before 
randomisation, had to undertake surgery irrespective of 
whether the woman was randomly assigned to the 
standard surgery group alone or the group with systematic 
lymphadenectomy. All women provided written, informed 
consent at initial recruitment to both the surgical and 
radiotherapy randomisation, in the event that they would 
be eligible for the radiotherapy trial. We obtained ethics 
approval for the trial from the North West Multi-centre 
Regional Ethics Committee (UK).
Interventions
We randomly allocated eligible women to the standard 
surgery group or lymphadenectomy group. Women in 
the standard surgery group had a hysterectomy and BSO, 
peritoneal washings, and palpation of para-aortic nodes. 
Nodes that were suspicious could be sampled if the 
surgeon believed it to be in the woman’s best interest. 
Women in the lymphadenectomy group had standard 
surgery plus a systematic dissection of the iliac and 
obturator nodes. If the nodes could not be dissected 
thoroughly because of obesity or anaesthetic concern, 
sampling of suspect nodes was recommended and 
para-aortic node sampling was at the discretion of the 
surgeon.
In both groups, a vertical incision was recommended, 
unless a transverse incision was preferred by the surgeon 
because of gross obesity. Surgery could be undertaken by 
laparoscopic technique provided that the procedure could 
be accomplished safely and as thoroughly as an open 
procedure. The type of surgical access (open or 
laparoscopic) to be used was speciﬁ ed before random-
isation and was therefore independent of the type of 
surgery allocated. During the trial we monitored the type 
of incision (vertical or transverse); when we noted an 
imbalance in the type of incisions being undertaken 
between the groups, the incision type also had to be 
speciﬁ ed before randomisation. Thrombo prophylaxis 
and prophylactic antibiotics were prescribed according to 
local practice. 
Yes No
Endometrial cancer thought preoperatively to be
conﬁned to the corpus
Is patient ﬁt to receive lymphadenectomy and
centre able to oﬀer lymphadenectomy
Randomise
Randomise
No external-beam
radiotherapy
Vault brachytherapy (if stated centre policy)
External-beam
radiotherapy
Standard surgery
group
Lymphadenectomy
group
Surgery according to
local standard practice
If intermediate-risk or high-risk early stage
Register pathology details with MRC Clinical Trials Unit
Low-risk
early stage
Treat according to local standard practice
Advanced
disease
Intermediate-risk or high-risk early stage
Figure 1: ASTEC trial design
Articles
www.thelancet.com   Vol 373   January 10, 2009 127
Procedures
Randomisation was done by a telephone call to the 
Medical Research Council Clinical Trials Unit (MRC 
CTU), and we used a method of minimisation. 
Stratiﬁ cation factors were centre, WHO performance 
status (0–1 vs 2–4), time since diagnosis (≤ 6 weeks 
vs >6 weeks), and planned surgical approach (open vs 
laparoscopic). We registered surgery and pathology 
details (based on local reporting) with the MRC CTU 
after surgery. We used the minimum dataset of the Royal 
College of Pathologists as the standard for pathology 
reporting.13 Women were classiﬁ ed in three categories: 
low-risk, early-stage disease (FIGO IA or IB and low 
grade pathology [G1, G2]); intermediate-risk and 
high-risk, early-stage disease (FIGO IA or IB with high 
grade pathology [G3, papillary serous or clear cell], 
FIGO IC or IIA); and advanced disease—ie, spread 
beyond the uterine corpus (FIGO stage IIB, IIIA, IIIB, 
and IV). Pelvic lymph-node status was not taken into 
account; thus no FIGO stage IIIC category was included.
Further randomisation into the ASTEC radiotherapy trial 
(comparing EBRT and observation with no EBRT or 
systemic treatment until recurrence) was required for 
women with intermediate-risk and high-risk, early-stage 
disease, including those with positive lymph nodes. 
Without this second randomisation, diﬀ erences in post-
surgical treatment could have arisen, with women in the 
standard surgery group either having more radiotherapy 
(because their lymph-node status was unknown) or less 
radiotherapy (because they were less likely to have positive 
lymph nodes identiﬁ ed) than women in the lymphaden-
ectomy group were having. We oﬀ ered women with 
low-risk, early-stage disease and women with advanced 
disease further treatment according to standard practice.
We assessed women before randomisation and 
surgery, 3 months after randomisation, then every 
3 months in the ﬁ rst year, every 6 months in years 2 
and 3, and every year thereafter. Follow-up data collected 
included details of endometrial cancer recurrence and 
treatment, vital status, and short-term and long-term 
toxic eﬀ ects. The primary outcome measure was overall 
survival. Secondary outcome measures were recurrence-
free survival, adverse eﬀ ects from treatment, and 
disease-speciﬁ c survival.
Statistical analysis
We planned to randomise 1400 women to detect an 
improvement in 5-year overall survival from 80% in the 
standard surgery group to 90% in the lymphadenectomy 
group (hazard ratio [HR] 0·47) with 5% signiﬁ cance level 
and 90% power. We allowed for non-compliance of 
roughly 20% in the sample size calculations to take 
account of women who would have no lymph nodes 
removed or have lymph node sampling only in the 
lymphadenectomy group.
We compared Kaplan-Meier curves for all time-to-event 
outcome measures with the standard (non-stratiﬁ ed) 
log-rank test. We deﬁ ned overall survival as the time from 
randomisation to death from any cause; women who 
were known to be still alive at the time of the analysis 
were censored at the time of their last follow-up. We 
deﬁ ned recurrence-free survival as the time from 
randomisation to ﬁ rst reappearance of endometrial 
cancer or death from any cause; women who were known 
1408 randomised
704 lymphadenectomy
 group
704 standard surgery 
 group
 2 no surgery 
  undertaken 
 685 TAH/BSO
 6 subtotal H/BSO
 11 surgery details 
  unknown
 35 nodes harvested
 88 died 
 616 alive at time of
  analysis
  Follow-up of 
  survivors
 64 at <1 year
 254 at 1–3 years
 179 at 3–5 years
 119 at ≥5 years
 103 died 
 601 alive at time of
  analysis
  Follow-up of 
  survivors
 44 at <1 year
 249 at 1–3 years
 196 at 3–5 years
 112 at ≥5 years
 3 no surgery 
  undertaken 
 693 TAH/BSO
 2 subtotal H/BSO
 6 surgery details 
  unknown
 630 nodes harvested
704 assessed for 
 primary endpoint
704 assessed for 
 primary endpoint
Figure 2: Proﬁ le of ASTEC surgical trial
We did not collect logs of patients assessed for eligibility. TAH=total abdominal 
hysterectomy. BSO=bilateral salpingo-oophorectomy. H=hysterectomy. 
Standard surgery
(N=704)
Lymphadenectomy
(N=704)
Age (years) 63 (36–89) 63 (34–93)
WHO performance status
0 520 (74%) 537 (76%)
1 156 (22%) 139 (20%)
2 23 (3%) 22 (3%)
3 4 (1%) 5 (1%)
4 1 (<1%) 1 (<1%)
Time between diagnosis and 
randomisation (weeks)
4 (0–16) 4 (0–26)
≤6 weeks 576 (82%) 588 (84%)
>6 weeks 128 (18%) 116 (16%)
Surgical technique intended
Open 650 (92%) 659 (94%)
Laparoscopic 54 (8%) 45 (6%)
Body-mass index 29 (16–79) 29 (10–69)
Unknown 161 177
Data are median (range) or number (%) unless otherwise speciﬁ ed.
Table 1: Baseline characteristics
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to be alive and without recurrent disease at the time of 
analysis were censored at the time of their last follow-up. 
Disease-speciﬁ c survival was deﬁ ned as time from 
randomisation to death from endometrial cancer or death 
due to treatment. To compare disease-speciﬁ c survival we 
undertook a competing risk analysis by subtracting the 
log-rank statistic for non-endometrial cancer deaths from 
the log-rank statistic for all deaths (ie, the two observed 
values were subtracted from each other, the two expected 
values were subtracted from each other, and the two 
variances were subtracted from each other).14
The Chief Investigator, blinded to treatment group, 
made the assessment of cause of death, and classiﬁ ed it as 
treatment related, disease related, treatment and disease 
related, or other (non-endometrial cancer, non-treatment 
related). All deaths within 30 days of surgery were 
classiﬁ ed as treatment related irrespective of their cause. 
All comparisons are expressed relative to women in the 
standard surgery group; therefore an HR less than 
1·0 indicates a decreased risk of the event for women in 
the lymphadenectomy group. We modelled the absolute 
diﬀ erence between the treatment groups using the ﬂ exible 
parametric models of Royston and Parmar.15
Although unadjusted HRs are presented for all outcome 
measures, we also calculated an adjusted HR with the 
Cox model for disease-speciﬁ c, overall, and recurrence-
free survival. Covariates included the characteristics: age 
(as a continuous variable), WHO performance status 
(0, 1, 2, 3, or 4), weeks between diagnosis and 
randomisation (≤6 weeks vs >6 weeks), surgical technique 
intended (open vs laparoscopic), and type of incision 
(vertical vs Pfannestiel vs other transverse, two dummy 
variables used); and pathology details: extent of tumour 
Standard 
surgery
(N=683)*
Lymphadenectomy
(N=686)*
Extent of tumour
Conﬁ ned to corpus uteri 553 (81%) 538 (79%)
Spread beyond corpus uteri 128 (19%) 146 (21%)
Extension to endocervical glands 33 (27%) 34 (24%)
Extension to cervical stroma 53 (43%) 57 (40%)
Extension beyond uterus 38 (31%) 52 (36%)
Unknown 4 3
Unknown 2 2
Histology
Endometriod 545 (80%) 541 (79%)
Adenocarcinoma NOS 46 (7%) 37 (5%)
Clear cell 10 (1%) 17 (2%)
Papillary serous 21 (3%) 32 (5%)
Squamous 6 (1%) 5 (1%)
Mucinous 1 (<1%) 4 (1%)
Mixed epithelial stromal 7 (1%) 8 (1%)
Sarcoma 10 (1%) 9 (1%)
Other epithelial 4 (1%) 6 (1%)
Mixed epithelial 31 (5%) 25 (4%)
Unknown 2 2
Diﬀ erentiation or grade
Well (G1) 225 (33%) 213 (31%)
Moderate (G2) 300 (44%) 290 (43%)
Poor (G3)† 139 (20%) 158 (23%)
Not applicable‡ 16 (2%) 16 (2%)
Unknown 3 9
Depth of invasion
Endometrium only 96 (14%) 89 (13%)
Inner half of myometrium 369 (55%) 310 (46%)
Outer half of myometrium 212 (31%) 274 (41%)
Unknown 6 13
Lymphovascular permeation
Present 125 (19%) 140 (22%)
Not present 407 (63%) 377 (59%)
Not stated 111 (17%) 127 (20%)
Unknown 40 42
(Continues in next column)
Standard 
surgery
(N=683)*
Lymphadenectomy
(N=686)*
(Continued from previous column)
Nodal involvement (if nodes harvested)
Yes 9 (27%) 54 (9%)
No 23 (72%) 560 (91%)
Unknown 0 1
Number of involved nodes
1 5 (56%) 28 (52%)
2 3 (33%) 12 (22%)
3 0 6 (11%)
4 0 2 (4%)
5 1 (11%) 4 (7%)
6 0 2 (4%)
Position of involved nodes
Unilateral 6 (67%) 31 (58%)
Bilateral 2 (22%) 19 (36%)
Para-aortic 1 (11%) 3 (6%)
Unknown 0 1
FIGO stage§
IA 88 (13%) 84 (12%)
IB 318 (47%) 261 (39%)
IC 147 (22%) 187 (28%)
IIA 33 (5%) 34 (5%)
IIB 53 (8%) 57 (8%)
III/IV 38 (6%) 52 (8%)
Unknown 6 11
Data are number (%) or number. NOS=not otherwise speciﬁ ed. *Excludes patients 
whose pathology details did not conﬁ rm endometrial cancer: 39 women 
(21 standard surgery group, 18 lymphadenectomy group) who had no other 
tumour in the surgical specimen; atypical hyperplasia; or cervical, ovarian, or 
colorectal cancer. †Including clear cell and serous papillary. ‡Sarcoma and mixed 
epithelial sarcoma. §FIGO IIIC is not included here. Women with positive lymph 
nodes are classiﬁ ed irrespective of nodal status. 
Table 2: Pathology details
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(conﬁ ned vs spread), histology (endometrioid/adeno-
carcinoma vs other), depth of invasion (inner half of myo-
metrium vs endometrium only, outer half of myo metrium 
vs endometrium only), and diﬀ erentiation (grade 1, 2, 
or 3). We assessed any beneﬁ ts of lymphaden ectomy on 
survival in an exploratory manner in subgroups. Pre-
deﬁ ned subgroups included grouping centres according 
to the median number of lymph nodes removed 
(<10, 10–14, ≥15) in the lymphadenectomy group, and 
grouping women by risk of recurrence: low risk of 
recurrence, intermediate and high risk of recurrence, and 
advanced disease (according to eligibility for the radio-
therapy randomisation). To test for diﬀ erences in the 
relative size of eﬀ ect in diﬀ erent subgroups, we used a 
χ² test for interaction, or, when appropriate, a χ² test for 
trend. All analyses were done on an intention-to-treat 
basis. All p values are two-sided. Analyses were undertaken 
with SAS System (version 9.10), apart from the ﬂ exible 
parametric models for which we used stata (version 9.1). 
This study is registered, number ISRCTN 16571884.
Role of the funding source
The sponsor of the study reviewed and approved the trial 
design, and the execution was overseen by an independent 
data monitoring committee and independent trial 
steering committee. The sponsor of the study had no role 
in data collection, data analysis, data interpretation, or 
writing of the report. The writing committee had full 
access to all the data in the study, and the trial 
management group had ﬁ nal responsibility for the 
decision to submit for publication.
Results
1408 women were randomly assigned: 704 to the standard 
surgery group and 704 to the lymphadenectomy group 
(ﬁ gure 2). Patient characteristics at randomisation were 
generally much the same between the two groups (table 1).
Table 2 summarises the pathology ﬁ ndings of women 
who were conﬁ rmed as having endometrial cancer at 
surgery. Most women (80%) had endometrioid endo-
metrial cancer (545/681 [80%] standard surgery group, 
541/684 [79%] lymphadenectomy group). Slightly more 
women had worse prognosis tumours with respect to 
histology (clear cell and papillary serous) and greater 
depth of invasion (10% more involvement of the outer 
half of the myometrium) in the lymphadenectomy group 
than in the standard surgery group (table 2).
Almost all women in both groups had a total abdominal 
hysterectomy and BSO (table 3). In the lymphadenectomy 
group, 58 (8%) women had no nodes removed because of 
anaesthetic concerns (n=22), obvious extra-uterine 
disease (12), obesity (9), withdrawal at patient request (9), 
or unknown reasons (6). We obtained the number of 
lymph nodes removed from the pathology report. In the 
lymphadenectomy group, 72 (12%) had one to four nodes 
removed and 396 (65%) women had ten or more 
removed (median 12 nodes). In the standard surgery 
group, of the 35 (5%) women who had any nodes removed 
(as was allowed within the protocol at the surgeon’s 
discretion), the median node count was two, and only 
Standard surgery 
(N=702)*
Lymphadenectomy 
(N=701)*
Surgery received
Total abdominal 
hysterectomy/BSO
685 (99%) 693 (99%)
Subtotal hysterectomy/BSO 6 (1%) 2 (<1%)
Unknown 11 6
Nodes harvested
Yes 35 (5%) 630 (92%)
No 652 (95%) 58 (8%)
Unknown 15 13
Number of nodes harvested
1–4 26 (76%) 72 (12%)
5–9 4 (12%) 142 (23%)
10–14 1 (3%) 153 (25%)
>14 3 (9%) 243 (40%)
Unknown 1 20
Median (range) 2 (1–27) 12 (1–59)
Required blood transfusion
Yes 30 (4%) 39 (6%)
Unknown 18 12
Number of units
1 2 (7%) 1 (3%)
2 13 (45%) 21 (54%)
3 6 (21%) 5 (13%)
4 6 (21%) 9 (23%)
≥5 2 (7%) 3 (8%)
Unknown 1 0
Median (range) 2 (1–6) 2 (1–7)
Length of operation (min)†
≤60 336 (52%) 83 (13%)
60–90 220 (34%) 285 (44%)
90–120 69 (11%) 190 (29%)
>120 25 (4%) 94 (14%)
Unknown 52 49
Median (range) 60 (10–255) 90 (10–390)
Number of postoperative days in hospital
Median (range) 6 (2–120) 6 (2–106)
Unknown 22 23
Surgical technique used
Laparoscopic 42 (6%) 45 (6%)
Open 647 (94%) 648 (94%)
Vertical incision 287 (45%) 384 (60%)
Pfannenstiel 311 (49%) 208 (32%)
Other transverse 43 (7%) 49 (8%)
Unknown 6 7
Unknown 13 8
Data are number (%) unless otherwise speciﬁ ed. BSO=bilateral salpingo-
oophorectomy. *Five women (two standard surgery group, three lymph adenectomy 
group) were unable to complete surgery. †Deﬁ ned as “from knife to skin”.
Table 3: Surgery details
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four women had ten or more removed. In the standard 
surgery group, surgeons mainly took biopsy samples of 
suspect nodes, which accounted for the diﬀ erence in the 
proportion of positive nodes in the standard surgery 
group compared with the lymphadenectomy group.
Women in both groups were managed in a similar way 
with respect to thromboprophylaxis, use of prophylactic 
antibiotics, type of anaesthetic, requirement for blood 
transfusion, and number of days spent in hospital 
(table 3). The median length of operation was 50% longer 
when lymphadenectomy was done (table 3). The pro-
portion of women having laparoscopic procedures was 
similar in both groups (table 3). More women in the 
standard surgery group had a transverse incision rather 
than a vertical incision compared with the lymphaden-
ectomy group. The risk of developing short-term major 
surgical complications was generally low in both groups 
but more women in the lymphadenectomy group than in 
the standard surgery group developed speciﬁ c 
complications of: ileus (18 [3%] vs eight [1%]), deep-vein 
thrombosis (six [1%] vs one [0·1%]), lymphocyst 
(ten [1%] vs two [0·3%]), and major wound dehiscence 
(ten [1%] vs two [0·3%]).
Table 4 summarises use of adjuvant radiotherapy for all 
randomised women. Similar proportions of women in 
both groups received postoperative radiotherapy. Of those 
who had radiotherapy, most had a combination of EBRT 
and brachytherapy (table 4). A few women with low-risk 
early-stage disease received radiotherapy and a smaller 
proportion received EBRT with or without brachytherapy 
(table 5). In the intermediate-risk and high-risk early-stage 
group, 137 (56%) and 138 (53%) women in the standard 
surgery and lymphadenectomy groups, respectively, 
Standard surgery
(N=683)*
Lymphadenectomy
(N=686)*
Low-risk early-stage endometrial cancer
Total 330 (49%) 282 (42%)
Radiotherapy received
Yes 22 (7%) 24 (9%)
No 305 (93%) 257 (91%)
Unknown 3 1
External beam +/- 
brachytherapy
12 (4%) 9 (3%)
Brachytherapy only 10 (3%) 15 (5%)
Nodes removed
Yes 8 (2%) 255 (92%)
No 314 (98%) 22 (8%)
Unknown 8 5
Median number of nodes 
(range)
2 (1–3) 12 (1–59)
Nodal involvement 
Yes (received EBRT) 1 (1) 6 (2)
No 7 249 
Intermediate-risk and high-risk early-stage endometrial cancer
Total 243 (36%) 264 (39%)
Radiotherapy received
Yes 137 (56%) 138 (53%)
No 106 (44%) 124 (47%)
Unknown 0 2
External beam +/- 
brachytherapy
102 (42%) 98 (37%)
Brachytherapy only 35 (14%) 40 (15%)
Nodes removed
Yes 14 (6%) 244 (93%)
No 226 (94%) 17 (7%)
Unknown 3 3
Median number of nodes 
(range)
1 (1–16) 12 (1–51)
Nodal involvement
Yes (received EBRT) 4 (1) 21 (12)
No 10 233
(Continues in next column)
Standard surgery
(N=683)*
Lymphadenectomy
(N=686)*
(Continued from previous column)
Advanced endometrial cancer
Total 103 (15%) 124 (19%)
Radiotherapy received
Yes 62 (61%) 64 (53%)
No 40 (39%) 56 (47%)
Unknown 1 4
External beam +/-
brachytherapy
55 (54%) 55 (46%)
Brachytherapy only 7 (7%) 8 (7%)
Nodes removed
Yes 10 (10%) 103 (85%)
No 91 (90%) 18 (15%)
Unknown 2 3
Median number of nodes 2 (1–6) 13 (1–38)
Nodal involvement
Yes (received EBRT) 4 (0) 25 (8)
No 6 78
Unknown, unable to classify risk group
Total 7 16
*Excludes patients whose pathology details did not conﬁ rm endometrial cancer. 
Table 5: Adjuvant radiotherapy received (within 3 months after 
surgery), nodes removed, nodal status, and external-beam 
radiotherapy (EBRT) received in node-positive patients by risk group 
deﬁ ned according to ASTEC radiotherapy eligibility
Standard 
surgery
(N=704) 
Lymphadenectomy
(N=704)
Radiotherapy received 227 (33%) 228 (33%)
External beam +/- 
brachytherapy
173 (25%) 165 (23%)
Brachytherapy only 54 (8%) 63 (9%)
Radiotherapy not received 471 (67%) 469 (67%)
Unknown 6 7
Table 4: Adjuvant radiotherapy received (within 3 months after surgery)
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received postoperative radiotherapy; 102 (42%) and 
98 (37%), respectively, received EBRT with or without 
brachytherapy. About half the women in this subgroup 
received EBRT as part of the ASTEC radiotherapy trial 
(46/102 standard surgery group and 51/98 lymphaden-
ectomy group). In the advanced disease group, a higher 
proportion of women in the standard surgery group than 
the lymphadenectomy group had radiotherapy and EBRT 
with or without brachy therapy (table 5).
A small proportion of women in both groups received 
other anticancer treatment during follow-up before disease 
recurrence, including chemotherapy (31 standard surgery 
group; 26 lymphadenectomy group) and progestogens 
(15 standard surgery group; 17 lymphaden ectomy group).
Within the treatment groups, the median number of 
nodes removed was similar in the three subgroups of 
low-risk early-stage, intermediate-risk and high-risk 
early-stage, and advanced disease (table 5). Within these 
subgroups, the proportion of women with nodes removed 
who had positive nodes in the lymphadenectomy group 
was 2·4% (six of 255 women), 9% (21 of 244), 
and 24% (25 of 103), respectively.
After adjuvant treatment, including postoperative 
radiotherapy in participants who received it, more women 
in the lymphadenectomy group than in standard surgery 
group reported moderate or severe morbidity or treatment-
related complications (119/684 [17%] vs 85/686 [12%]). Of 
the 26 women (two standard surgery group; 
24 lymph aden ectomy group) who had lymphoedema, eight 
received EBRT (all in lymphaden ectomy group). In the 
lymph adenectomy group we noted no clear evidence of an 
asso ciation between EBRT and lymphoedema (relative risk 
1·57 [95% CI 0·66–3·74]; p=0·28).
By May, 2006, with a median follow up of 37 months 
(IQR 24–58 months), 191 (14%) women had died (table 6). 
Overall survival curves showed no evidence of a diﬀ erence 
between the two groups (ﬁ gure 3).
Deaths were classiﬁ ed as treatment related, or disease 
and treatment related, in four (0·6%) women in the 
standard surgery group and nine (1·3%) in the 
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 Events Totals
Standard        107      704
Lymphadenectomy        144      704
 Number at risk
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Figure 3: Overall survival (A), disease and treatment-related deaths (B), and recurrence-free survival (C) by 
treatment group
Standard 
surgery
(N=704)
Lymphadenectomy
(N=704)
Total deaths 88 (13%) 103 (15%)
Disease related 56 (65%) 64 (63%)
Treatment related* 4 (5%) 7 (7%)
Disease and treatment related* 0 2 (2%)
Not disease or treatment related 26 (30%) 28 (28%)
Unknown 2 2
*Details of treatment related, and disease and treatment related, cause of death: 
standard surgery group—renal failure (n=1), perforated ulcer (1), pulmonary 
oedema (1), bowel ischaemia (1); lymphadenectomy group—pulmonary 
embolism (2), perforated duodenal ulcer (1), perforated diverticular disease (1), 
bowel obstruction (1), bowel infarction (1), deep-vein thrombosis and 
infection (1), aspiration (1), no details (1).
Table 6: Cause of death
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lymphadenectomy group (table 6). A third of the deaths 
were not related to treatment or disease (26/88 deaths in 
standard surgery group and 28/103 in lymphadenectomy 
group). 54 deaths were classiﬁ ed as non-disease and 
non-treatment related (table 6). We therefore undertook a 
competing risk analysis that takes this factor into account. 
An analysis of disease or treatment-related deaths again 
showed an HR in favour of the standard surgery group 
(ﬁ gure 3), although inevitably the conﬁ dence intervals 
were wider since there were fewer events in this analysis.
173 (12%) women had had disease recurrence 
(75 standard surgery group, 98 lymphadenectomy group), 
and 251 (18%) had died or had recurrence of disease 
(107 standard surgery group, 144 lymphadenectomy 
group) at the time of analysis. Table 7 summarises the site 
of recurrence.
Kaplan-Meier curves for recurrence-free survival 
showed a conventionally signiﬁ cant beneﬁ t for the 
standard surgery group (ﬁ gure 3). Figure 4 shows the 
Kaplan-Meier plots for overall survival and recurrence-free 
Standard surgery
(N=704)
Lymphadenectomy
(N=704)
Total recurrences 75 (11%) 98 (14%)
Local/vaginal 18 (25%) 24 (27%)
Pelvic 11 (15%) 10 (11%)
Distal 38 (53%) 49 (54%)
Local/vaginal and distal 0 3 (3%)
Pelvic and distal 5 (7%) 4 (4%)
Unknown 3 8
Table 7: Site of recurrence
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Figure 4: Kaplan-Meier plots for the two treatment groups for overall and recurrence-free survival together with the model curves from ﬁ tting the 
Royston-Parmar parametric model
A and B show Kaplan-Meier estimates, with Royston-Parmar parametric model ﬁ tted. C and D show the absolute diﬀ erence over time (95% CI) in survival from 
Royston-Parmar parametric model.
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survival together with the model curves from ﬁ tting the 
Royston-Parmar parametric model, as well as the absolute 
diﬀ erence between the treatment groups over time. The 
absolute diﬀ erence in 5-year overall survival estimated 
from these curves was a 1% (95% CI –4·0 to 6) 
improvement in favour of standard surgery (ﬁ gure 4). 
The 5-year overall survival was 81% (95% CI 77–85) in the 
standard surgery group and 80% (76–84) in the 
lymphadenectomy group. The absolute diﬀ erence in 
5-year recurrence-free survival was 6% (1–12) in favour of 
standard surgery (ﬁ gure 4). 5-year recurrence-free 
survival was 79% (75–83) in the standard surgery group 
and 73% (69–77) in the lymphadenectomy group. Over 
time, the absolute diﬀ erence in overall survival between 
the two groups remained close to zero, whereas the 
absolute diﬀ erence for recurrence-free survival increased 
over time in favour of standard surgery (ﬁ gure 4).
Despite randomisation of a large number of women, 
we recorded some diﬀ erences in the pretreatment 
characteristics with respect to histological features that 
suggested women in the standard surgery group might 
be at lower risk of recurrence than were those in the 
lymphadenectomy group. Results of analyses adjusting 
for these imbalances (table 8) gave an HR closer to 1·0 for 
both overall survival and recurrence-free survival, and 
did not suggest a beneﬁ t with lymphadenectomy for 
overall survival (adjusted HR 1·04 [95% CI 0·74–1·45]; 
p=0·83) or for recurrence-free survival (1·25 [0·93–1·66]; 
p=0·14), with the point estimate for recurrence-free 
survival still in favour of standard surgery. 
We also undertook analyses of disease-speciﬁ c survival, 
adjusting for baseline characteristics with the Cox model 
(table 8). Results were similar to the unadjusted analysis 
(table 8). Exploratory interaction analyses did not provide 
any evidence that the eﬀ ect of lymphadenectomy on 
overall survival or recurrence-free survival diﬀ ered in 
subgroups deﬁ ned by age, WHO performance status, 
and pathological features of endometrial cancer including 
depth of invasion, histology, or grade of tumour (data not 
shown). We did a predeﬁ ned analysis to explore the eﬀ ect 
of number of nodes removed for systematic lymph node 
dissection in an unbiased manner by classifying centres 
according to the median number of nodes removed in 
the lymphadenectomy group: less than ten, between ten 
and 14, and 15 or more nodes (table 9). Our results 
suggest that, if anything, lymphadenectomy could be 
associated with a worse outcome the more lymph nodes 
removed (table 9; p=0·13 for overall survival and p=0·16 for 
recurrence-free survival). Results of the adjusted analyses 
by hospitals removing diﬀ erent median numbers of 
nodes (table 9) lends support to this conclusion.
In the subgroups of women classiﬁ ed with low-risk 
early-stage disease, intermediate-risk and high-risk 
early-stage disease, and advanced disease (ﬁ gure 5), we 
recorded no evidence of a diﬀ erence in the relative eﬀ ect 
of lymphadenectomy versus standard surgery (p=0·55 for 
overall survival and p=0·35 for recurrence-free survival).
Discussion
This randomised trial has shown no evidence of a beneﬁ t 
for systematic lymphadenectomy for endometrial cancer 
in terms of overall, disease-speciﬁ c, and recurrence-free 
survival. This study is one of the largest reported surgical 
gynaecological cancer trials. We undertook searches to 
identify other published randomised trials of 
lymphadenectomy in endometrial cancer and searched 
the Cochrane database for systematic reviews of both 
randomised and observational studies.14 None was found 
but a randomised trial (smaller than ASTEC) has just 
been reported, which conﬁ rms that lymphadenectomy is 
not associated with a survival beneﬁ t in endometrial 
cancer.15
The proportion of women with pelvic-node metastases 
in ASTEC (9%) was consistent with that in the 
Gynaecological Oncology Group (GOG) surgical study of 
disease spread.6 The ASTEC trial design successfully 
randomised participants to postoperative EBRT 
independent of lymph-node status, resulting in a balanced 
proportion of irradiated women in both groups. 
Lymphadenectomy might otherwise have led to more 
women categorised as having high-stage disease in the 
lymphadenectomy group, which would have resulted in 
more women in this population receiving postoperative 
EBRT. Thus, any eﬀ ect in favour of the lymphadenectomy 
Overall survival Recurrence-free survival Disease-speciﬁ c survival Recurrence-free 
disease-speciﬁ c survival 
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Unadjusted with full data (n=1408) 1·16 (0·87–1·54) 0·31 1·35 (1·06–1·73) 0·017 1·21 (0·86–1·70) 0·28 1·46 (1·11–1·23) 0·01
Adjusted* by covariates
(n=1337 with imputation by mean for 
unknown baseline)†
1·04 (0·74–1·45) 0·83 1·25 (0·93–1·66) 0·14 1·12 (0·75–1·69) 0·57 1·33 (0·96–1·83) 0·083
HR=hazard ratio. *Adjusted for age (continuous), WHO performance status (0, 1, 2, 3, or 4), weeks between diagnosis and randomisation (≤6 weeks vs >6 weeks), surgical 
technique intended (open vs laparoscopic), type of incision (vertical vs Pfannenstiel vs other transverse), extent of tumour (conﬁ ned vs spread), histology 
(endometrioid/adenocarcinoma vs other), depth of invasion (inner half vs endometrium, outer half vs endometrium),  diﬀ erentiation (grade 1, grade 2, grade 3), and centre 
(dummy variables and centres with less than ﬁ ve patients being grouped as one new centre). †71 patients were not included (37 standard surgery group, 
34 lymphadenectomy group): 39 with no disease and 32 with diﬀ erentiation not applicable (histology mixed epithelial stromal, sarcoma). 
Table 8: Unadjusted and adjusted analysis using the Cox model for overall survival and recurrence-free survival (deaths from all causes), and for 
disease-speciﬁ c survival and recurrence-free disease-speciﬁ c survival (disease and treatment speciﬁ c deaths only)
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group would have been enhanced. Although more women 
in the standard surgery group than in the lymphaden-
ectomy group, apart from in the low-risk early-stage 
subgroup, received EBRT (which might favour standard 
surgery), diﬀ erences were not large. Furthermore, a 
greater proportion of women in the lymphadenectomy 
group with positive lymph nodes received EBRT (which 
might favour lymphadenectomy), although numbers were 
small. However, in view of the results of the systematic 
review and meta analysis of 1770 women from four 
randomised trials7 and now data from the ASTEC/EN.5 
radiotherapy trial8 showing that even a very small beneﬁ t 
of radiotherapy (more than 3% in 5-year overall survival) 
can be excluded, this slight imbalance in the use of EBRT 
is neither statistically nor clinically signiﬁ cant.
Several observational studies have compared outcomes 
in women who have received systematic lymphadenectomy 
and those who have not, with some studies supporting 
lymphadenectomy for all grades of tumour,10,16–18 another 
supporting it for G3 tumours,12 and others suggesting 
that beneﬁ t depends on the number of lymph nodes 
removed.17,19,20 However, these studies of treatment beneﬁ t 
should be interpreted with caution since they are prone to 
bias because of systematic diﬀ erences in women who do 
and do not receive lymphadenectomy, including 
comorbidity and obesity that can be related to poor 
survival. Additionally, non-randomised studies will always 
have a higher proportion of node-positive women with 
occult stage III disease in the group who have not been 
surgically staged versus those classiﬁ ed as stage I after 
lymphadenectomy with negative nodes and a reduced 
risk of recurrence (stage migration). Large cancer 
registries are invaluable for monitoring trends in cancer 
incidence and outcomes, for hypothesis generation, and 
for planning the provision of cancer services, but they are 
not reliable for assessment of treatment eﬀ ects. Analysis 
of large observational cohorts means that small 
associations could be signiﬁ cant but they can easily arise 
from very modest bias and should not be misinterpreted 
as measuring a direct eﬀ ect of an intervention.
No national or international accepted guidelines exist 
for what is regarded as an adequate systematic lymphaden-
ectomy in terms of node counts, and therefore no speciﬁ c 
guidelines were given in the protocol. The number of 
nodes identiﬁ ed might depend on the physical 
characteristic of the women, surgical thoroughness, and 
pathological examination of the tissues. ASTEC succeeded 
in comparing systematic lymphadenectomy with a more 
conservative approach of standard surgery with 
lymphadenectomy in women who only had potentially 
positive nodes on palpation. The median lymph-node 
count of 12 in the lymphadenectomy group is broadly 
similar to that in a large single-institution case series from 
the USA, in which 11 nodes were removed,16 as well as a 
study using data from an large observational database in 
which a median of between seven and 12 nodes were 
removed.20 
We were unable to undertake an unbiased analysis of 
outcome according to the number of nodes removed for 
individual patients, since we would have had to break the 
randomised comparison with the same issues of selection 
bias (although less stage shift). We were, however, able to 
do the exploratory analysis that considered standard 
surgery versus lymphadenectomy in centres which 
routinely removed diﬀ erent numbers of nodes. Results 
from this analysis suggested that, if anything, the 
lymphadenectomy group had poorer outcomes when more 
nodes were removed than the standard surgery group did. 
This ﬁ nding and the trend of a slightly higher recurrence 
in the lymphadenectomy group is potentially important, 
Overall survival Recurrence-free 
survival
Centres with median LN count <10 
Unadjusted (n=489) 0·81 (0·50–1·31) 1·01 (0·67–1·54)
Adjusted* (n=481) 0·54 (0·31–0·95) 0·72 (0·45–1·16)
Centres with median LN count 10–14
Unadjusted (n=314) 1·40 (0·74–2·64) 1·72 (1·00–2·96)
Adjusted* (n=307) 1·39 (0·67–2·90) 1·81 (0·99–3·27)
Centres with median LN count ≥15
Unadjusted (n=553) 1·57 (1·00–2·45) 1·71 (1·14–2·56)
Adjusted* (n=536) 1·37 (0·83–2·26) 1·50 (0·95–2·37)
Data are hazard ratio (95% CI). LN=lymph node. *Adjusted by covariates (with 
imputation by mean for unknown baseline) for age (continuous), WHO 
performance status (0, 1, 2, 3, or 4), weeks between diagnosis and randomisation 
(≤6 weeks vs >6 weeks), surgical technique intended (open vs laparoscopic), type 
of incision (vertical vs Pfannenstiel vs other transverse), extent of tumour 
(conﬁ ned vs spread), histology (endometrioid/adenocarcinoma vs other), depth 
of invasion (inner half vs endometrium, outer half vs endometrium), and 
diﬀ erentiation (grade 1, grade 2, grade 3).
Table 9: Unadjusted and adjusted analysis classifying centres by median 
number of nodes harvested, with the Cox model for overall survival and 
recurrence-free survival
Overall survival
Risk group
Low-risk early stage
High-risk early stage
Advanced
Trend χ2=0·01, df=1, p=0·920; interaction test: χ2=1·19, df=2, p=0·552
16/282
42/264
42/124
Number events/number entered
13/330
38/243
31/103
2·43
–1·10
4·26
7·21
19·75
18·12
0 0·5 1 2 5
Lymphadenectomy
better
Standard
better
Lyphadenectomy Standard
O–E Variance Hazard ratio (ﬁxed)
Recurrence-free survival
Risk group
Low-risk early stage
High-risk early stage
Advanced
Trend χ2=0·63, df=1, p=0·427; interaction test: χ2=2·08, df=2, p=0·353
31/282
57/264
51/124
19/330
44/243
37/103
7·81
3·23
5·97
12·43
25·11
21·89
A
B
Figure 5: Eﬀ ect of lymphadenectomy on overall survival (A) and recurrence-free survival (B) in women in 
diﬀ erent risk groups of recurrence
O–E=observed minus expected. Outer bars show 99% CI, inner bars show 95% CI.
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although an explanation is not obvious. Although some 
node sampling occurred in the standard surgery group, 
only 35 (5%) women had any nodes removed and, of 
these, 26 women had four or fewer removed. This small 
amount of non-compliance could have biased the point 
estimate for the HR very slightly towards 1 (ie, no eﬀ ect of 
lymphadenectomy) but the treatment eﬀ ect would have to 
have been very large for this small amount of 
non-compliance to aﬀ ect the overall result.
One limitation of this study is that the lymphaden-
ectomy speciﬁ ed in the protocol was not comprehensive 
and did not include all pelvic and para-aortic nodes. At the 
time ASTEC was conceived, the systematic lymph-
adenectomy (ie, lymphadenectomy rather than sampling) 
was considered to be a potentially therapeutic procedure 
that could be implemented in the range of hospitals where 
women with endometrial cancer are treated and in the 
range of women needing it, including those in whom 
more extensive surgery might be diﬃ  cult because of lack 
of surgical access due to obesity. More extensive 
lymphadenectomy could have had signiﬁ cantly increased 
treatment-related morbidity and mortality. Data for 
sentinel nodes have given insight into the totality of the 
lymph drainage pattern in endometrial cancer and might 
well direct future surgical research. Improvements in 
imaging could also make selection of high-risk women 
easier so that a more extensive lymphadenectomy could 
be done in the subset of women for whom lymph-node 
metastases are more likely and a more extensive operation 
is feasible (those with little comorbidity, including 
obesity).
Morbidity was low overall, but we noted a substantial 
increase in the incidence of lymphoedema in the 
lymphadenectomy group compared with standard 
surgery. Clinicians might not have noted or reported 
milder cases, since all reported cases of lymphoedema 
were moderate and severe.
We acknowledge that although ASTEC is a very large 
trial, only 191 deaths were recorded. Could a small but 
important treatment eﬀ ect have been missed? 
Recurrence-free survival is the most powerful outcome 
measure (with 251 events). The lower limit of the 95% CI 
for the adjusted HR for recurrence-free survival (table 8) 
of 0·93 translates into a beneﬁ t of 1·5% at 5 years 
(adjusted). Thus we can reliably exclude an improvement 
in 5-year recurrence-free survival from lymphaden-
ectomy of 1·5% or greater.
ASTEC has important implications for both clinical 
practice and future trials. The balance of risks and beneﬁ ts 
for systematic lymphadenectomy does not favour this 
intervention, with no clear evidence of beneﬁ t in terms of 
overall or recurrence-free survival and increased risk of 
lymphoedema. Although the results do not invalidate the 
use of lymphadenectomy for surgical staging to identify 
the need for adjuvant treatment, our results suggest that 
lymphadenectomy in itself has no therapeutic eﬀ ect and is 
therefore not justiﬁ ed as a therapeutic procedure in its 
own right. Some argue that surgical staging allows the 
most rational use of adjuvant radiotherapy, reserving it for 
women with proven extrauterine disease. In doing so, 
long-term eﬀ ects associated with radiotherapy can be 
reduced without aﬀ ecting survival. This argument might 
be an over simpliﬁ ed view of the evidence, since results of 
GOG99 study showed that when surgically staged women 
with negative nodes were randomly assigned, a protective 
eﬀ ect of radiotherapy against pelvic recurrence was still 
recorded although no evidence of a diﬀ erence in overall 
survival was noted (incidence of recurrence was 12% in 
the no radiotherapy group and 3% in the radiotherapy 
group, relative hazard 0·42 [90% CI 0·25–0·73]; p=0·007).21 
Estimated overall 4-year survival was 86% in the no 
radiotherapy group and 92% for group with radiotherapy 
(relative hazard 0·86 [90% CI 0·57–1·29]; p=0·56). This 
ﬁ nding suggests that the decision regarding adjuvant 
therapy for intermediate-risk and high-risk disease should 
be made independently of lymph-node status.
In conclusion, this large randomised trial suggests that 
unless surgical staging will directly aﬀ ect adjuvant 
therapy, routine systematic pelvic lymphadenectomy 
cannot be recommended in women undergoing primary 
surgery for stage I endometrial cancer outside of clinical 
trials. Surgical interventions should be assessed through 
randomised trials, and surgical staging as part of a 
management strategy is no exception.
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